Abstracts tagged "Biomarkers"

Abstract Number: 2365 • ACR Convergence 2023
Decoding the Peripheral Immune Landscape of Systemic Sclerosis to Investigate Disease Stages and Interstitial Lung Disease Progression
Vasuki Ranjani Chellamuthu¹, Maria Noviani², Ahmad bin Mohamed Lajam¹, Andrea Hsiu Ling Low² and Salvatore Albani¹, ¹Translational Immunology Institute, SingHealth, Singapore, Singapore, ²Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Systemic sclerosis (SSc) is a heterogenous autoimmune disease characterized by fibrosis, vascular abnormalities and immune dysregulation. Characterization of peripheral blood immune signatures in relation…
Abstract Number: 2578 • ACR Convergence 2023
Machine Learning Identifies New Sporadic Inclusion Body Myositis Endotypes Associated with Unique Autoantibody Profiles
Jenny Wei¹, Mark Tarnopolsky², Marie Hudson³, Ross Mitchell⁴, Katherine Buhler⁵, Antoine Dufour⁶, Luiz de Almeida⁶, Paul R. Fortin⁷, Eric Boilard⁸, Yann Becker⁸, Erin Hatcher², Mei Feng Zhang⁶, Marvin Fritzler⁶ and May Choi⁶, ¹University of Toronto, Toronto, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Calgary; Cumming School of Medicine, Calgary, AB, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ⁸Université Laval, Quebec City, QC, Canada
Background/Purpose: Sporadic inclusion body myositis (sIBM) is a subset of autoimmune inflammatory myopathies (AIM) that is often challenging to diagnose. The objective of this study…
Abstract Number: 0099 • ACR Convergence 2023
Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases
Doruk Erkan¹, JoAnn Vega¹, Tyler O'Malley² and Andrew Concoff³, ¹Hospital for Special Surgery, New York, NY, ²Exagen, Vista, CA, ³Exagen, Los Angeles, CA
Background/Purpose: Based on animal models, complement activation is part of Antiphospholipid Syndrome (APS) pathogenesis. However, studies investigating complement activation in antiphospholipid antibody (aPL)-positive patients are…
Abstract Number: 0529 • ACR Convergence 2023
Sex-dependent Differences in Disease Characteristics Do Not Influence Effectiveness of Secukinumab Therapy in Patients with Active Axial Spondyloarthritis in a Non-Interventional Trial (AQUILA)
Michaela Koehm¹, Maximilian Klippstein², Sabine Kugler³, Sina Mackay³, Daniel Schulz³, Asmir Vodencarevic⁴, Guillaume Wendt⁴, Daniel Peterlik⁴, Uta Kiltz⁵, Jan Brandt-Juergens⁶ and Frank Behrens⁷, ¹University Hospital Frankfurt, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Frankfurt, Germany, ³Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Sankt Augustin, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Individualized treatment strategies are of high importance in the treatment of patients with axial spondyloarthritis (axSpA). IL-17A inhibition has demonstrated good efficacy on axSpA.…
Abstract Number: 0602 • ACR Convergence 2023
Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus
Elizabeth Repash, Tiffany Blair, Amanda Enstrom, Lawrence Evans, Susan Debrot, Katherine Lewis, Armand Bankhead, Stanford Peng and Stacey Dillon, Alpine Immune Sciences, Inc., Seattle, WA
Background/Purpose: CD28 and inducible T cell costimulator (ICOS) play nonredundant roles in T cell activation and inhibiting these pathways can ameliorate an (auto)immune response. Systemic…
Abstract Number: 0850 • ACR Convergence 2023
Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis
Andrea Fava¹, Mohamed G. Atta¹, Jose Monroy-Trujillo², Derek Fine², Daniel Goldman³, Izmirly peter⁴, H Michael Belmont⁵, the Accelerating Medicines Partnership in RA/SLE⁶, Jill Buyon⁷ and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴NYU, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶Multiple, Multiple, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: One third of lupus nephritis (LN) patients develop irreversible kidney damage despite achieving a clinical response based on resolution of proteinuria. Furthermore, per protocol…
Abstract Number: 1142 • ACR Convergence 2023
A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease
Nikita Jhawar, Claire Wilson, Andy Abril, Li Zhuo and Yaohua Ma, Mayo Clinic, Jacksonville, FL
Background/Purpose: Connective tissue diseases such as scleroderma are frequently associated with interstitial lung disease (ILD). Detection of autoantibodies is crucial in characterizing disease phenotypes, but…
Abstract Number: 1379 • ACR Convergence 2023
Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome
Kenneth Der¹, Ryan Crass², Brendan Smith³, Wonkyung Byon⁴, Yan Xin⁵ and Jiayin Huang⁶, ¹Horizon Therapeutics, Danville, CA, ²Apellis Pharmaceuticals, Michigan, ³A2-Ai, Michigan, ⁴Amador Bioscience, Michigan, ⁵Horizon Therapeutics, South San Francisco, CA, ⁶Horizon Therapeutics, Chicago, IL
Background/Purpose: Sjögren's (SjS) is a chronic, systemic autoimmune disease caused by aberrant activation and infiltration of lymphocytes. Dazodalibep (DAZ), a novel non-antibody biologic antagonist of…
Abstract Number: 1693 • ACR Convergence 2023
Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures
Alice Horisberger¹, Alec Griffith¹, Arnon Arazi², Joshua Keegan¹, Kaitlyn Howard¹, Takanori Sasaki¹, Tusharkanti Ghosh³, Andrea Fava⁴, Jun Inamo⁵, John Pulford¹, Ekaterina Murzin¹, Brandon Hancock¹, Katie Preisinger⁶, Maria Gutierrez-Arcelus⁷, Thomas Eisenhaure⁸, Joel Guthridge⁹, Paul Hoover¹⁰, Maria Dall'Era¹¹, David Wofsy¹¹, Diane L. Kamen¹², Kenneth Kalunian¹³, Richard Furie¹⁴, H Michael Belmont¹⁵, Peter Izmirly⁶, Robert Clancy¹⁶, David Hildeman¹⁷, steve Woodle¹⁷, William Apruzzese¹⁸, Maureen McMahon¹⁹, Jennifer Grossman²⁰, Jennifer Barnas²¹, Fernanda Payan-Schober²², Mariko Ishimori²³, Accelerating Medicines Partnership Program RA SLE Network²³, Matthias Kretzler²⁴, Celine Berthier²⁴, Jeff Hodgin²⁴, Dawit Demeke²⁴, Chaim Putterman²⁵, Nir Hacohen⁸, Michael Brenner¹, Jennifer Anolik²¹, Anne Davidson²⁶, Judith James⁹, Soumya Raychaudhuri¹⁰, Michelle Petri²⁷, Jill Buyon¹⁶, Betty Diamond²⁶, The Accelerating Medicines Partnership In RA/SLE²⁸, Fan Zhang²⁹, James Lederer¹ and Deepak Rao¹⁰, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Broad Institute of MIT and Harvard, Melrose, MA, ³School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, ⁴Johns Hopkins University, Baltimore, MD, ⁵University of Colorado School of Medicine, Aurora, CO, ⁶New York University School of Medicine, New York, NY, ⁷Boston Children's Hospital, Boston, MA, ⁸Broad Institute of MIT and Harvard, Cambridge, MA, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹University of California San Francisco, San Francisco, CA, ¹²Medical University of South Carolina, Charleston, SC, ¹³University of California San Diego, La Jolla, CA, ¹⁴Northwell Health, Manhasset, NY, ¹⁵NYU School of Medicine, New York, NY, ¹⁶NYU Grossman School of Medicine, New York, NY, ¹⁷University of Cincinnati College of Medicine, Cincinnati, OH, ¹⁸Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, ¹⁹UCLA David Geffen School of Medicine, Los Angeles, CA, ²⁰University of California Los Angeles, Los Angeles, CA, ²¹University of Rochester Medical Center, Rochester, NY, ²²Texas Tech University Health Sciences Center, El Paso, TX, ²³Cedars-Sinai Medical Center, Los Angeles, CA, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Albert Einstein College of Medicine, Bronx, NY, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁸multisites, multisites, ²⁹University of Colorado, Aurora, CO
Background/Purpose: Patients with lupus nephritis (LN) have variable responses to standard-of-care therapy, and a third of patients with class III, IV, or V show a…
Abstract Number: 1795 • ACR Convergence 2023
Multi-Omics Analyses Identify Metabolic Pathways That Differentiate Psoriatic Arthritis from Psoriasis
Chiara Pastrello¹, Darshini Ganatra², Max Kotlyar¹, Nikita Looby², Quan Li³, Lihi Eder⁴, Dafna Gladman⁵, Proton Rahman³, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁴Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁷Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a form of inflammatory arthritis that occurs in patients with cutaneous psoriasis. Due to the lack of clinically useful diagnostic…
Abstract Number: 2297 • ACR Convergence 2023
Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
Laura Patricia Whittall Garcia¹, Dafna Gladman², Murray Urowitz³, Zahi Touma⁴ and Joan Wither¹, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Type I Interferons (IFN-I) play a role in SLE and Lupus Nephritis (LN) pathogenesis. We have recently shown that IFN-I gene expression predicts the…
Abstract Number: 2368 • ACR Convergence 2023
Is Skin Disease a Local Manifestation of Systemic Tissue Turnover? Serological Collagen Biomarkers Provide Important Information on Skin Diseases Arising from Mutations in Collagen Genes
Signe Holm Nielsen¹, Matej Anđelić², Dovile Sinkeviciute¹, Anne-Christine Bay-Jensen¹ and Morten Karsdal¹, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Copenhagen, Denmark
Background/Purpose: Collagens are the main constituents of the skin. Genetic mutations in type VI, VII, and XVII collagen cause skin diseases, such as atopic dermatitis,…
Abstract Number: 2584 • ACR Convergence 2023
Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis
Benoît Thomas P. GILBERT¹, Raul Yhossef TITO TADEO², Céline LAMACCHIA¹, Olivia STUDER¹, Delphine COURVOISIER¹, Jeroen RAES³ and Axel Finckh⁴, ¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium, ³Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven., Leuven, Belgium, ⁴HUG, Geneva, Switzerland
Background/Purpose: We attempted to replicate and expand previous findings of an increased abundance of Prevotellaceae in early untreated Rheumatoid Arthritis (RA) or its preclinical stages,…
Abstract Number: 0101 • ACR Convergence 2023
Non-Criteria Antiphospholipid Antibodies and Calprotectin as Potential Biomarkers in Pediatric Antiphospholipid Syndrome
Elizabeth Sloan¹, Katarina Kmetova², NaveenKumar K. Somanathapura², Lyndsay Kluge², Emily Chong², Claire Hoy², Srilakshmi Yalavarthi², Jacqueline Madison², Cyrus Sarosh², Lynnette Walters³, Jeanine Baisch⁴, Jessica Turnier², Virginia Pascual⁴, Tracey Wright¹, Jason Knight², Ayesha Zia¹ and Yu Zuo², ¹UT Southwestern, Dallas, TX, ²University of Michigan, Ann Arbor, MI, ³Scottish Rite Hospital for Children, Dallas, TX, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: While classification criteria for pediatric APS are not yet available, recent research suggests pediatric APS patients are unique, and many present with extra-criteria manifestations…
Abstract Number: 0544 • ACR Convergence 2023
Autoantibodies to dsDNA and Associated Proteins: Association with Proteinuria and Lupus Nephritis
Ranjan Gupta¹, Amita Aggarwal², Avinash Jain³, Liza Rajasekhar⁴, Chengappa Kavadichanda⁵, Vineeta Shobha⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Bidyut Das⁹ and Manish Rathi¹⁰, ¹All India Institute of Medical Sciences, New Delhi, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ³SMS Medical College, Lucknow, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁶St. John's National Academy of Health Science, Bangalore, India, ⁷Christian Medical College, Vellore, India, ⁸Govt of West Bengal, Kolkata, India, ⁹SCB medical college, Cuttack, India, ¹⁰Postgraduate Institute of Medical education and Research, Chandigarh, India
Background/Purpose: Anti-dsDNA antibodies (ADA) are traditionally measured by ELISA and are associated with Lupus nephritis (LN). Testing by immunoline assay (IL) provides additional information on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].